Truist Financial Begins Coverage on IQVIA (NYSE:IQV) – MarketBeat

Analysts at Truist Financial initiated coverage on shares of IQVIA (NYSE:IQV – Get Rating) in a research note issued on Friday, The Fly reports. The firm set a “buy” rating on the medical research company’s stock.

→ Unusual Passive Income Investment (Found on a Golf Course) (From Oxford Club)

Several other analysts have also recently commented on IQV. Cowen began coverage on IQVIA in a report on Tuesday, December 6th. They issued an “outperform” rating and a $251.00 price target for the company. Credit Suisse Group restated an “outperform” rating and issued a $265.00 price target on shares of IQVIA in a report on Monday, February 13th. JPMorgan Chase & Co. lifted their price target on IQVIA from $257.00 to $263.00 and gave the company an “overweight” rating in a report on Monday, February 27th. Cowen initiated coverage on IQVIA in a report on Tuesday, December 6th. They issued an “outperform” rating for the company. Finally, Morgan Stanley lifted their price objective on IQVIA from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, February 13th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $256.27.

IQVIA Trading Up 0.6 %

IQVIA stock opened at $196.43 on Friday. The stock has a market cap of $36.56 billion, a PE ratio of 34.40, a P/E/G ratio of 1.97 and a beta of 1.40. The stock has a 50-day moving average price of $219.23 and a 200 day moving average price of $208.91. IQVIA has a 52 week low of $165.75 and a 52 week high of $254.94. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV – Get Rating) last posted its quarterly earnings data on Friday, February 10th. The medical research company reported $2.78 EPS for the quarter, topping analysts’ consensus estimates of $2.76 by $0.02. The firm had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.71 billion. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.42 EPS. Equities research analysts predict that IQVIA will post 9.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 4,446 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at approximately $445,128.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IQVIA news, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at approximately $445,128.53. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the insider now directly owns 17,053 shares in the company, valued at $3,922,190. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently made changes to their positions in the business. Bishop Rock Capital L.P. increased its holdings in shares of IQVIA by 14,549.4% in the 2nd quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock valued at $18,667,000 after acquiring an additional 4,022,902 shares during the last quarter. Norges Bank bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $408,232,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of IQVIA by 1,852.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,066,764 shares of the medical research company’s stock valued at $423,466,000 after acquiring an additional 1,960,914 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 1,170.9% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,364,641 shares of the medical research company’s stock valued at $247,191,000 after acquiring an additional 1,257,263 shares during the last quarter. Finally, Alliancebernstein L.P. increased its holdings in shares of IQVIA by 20.1% in the 3rd quarter. Alliancebernstein L.P. now owns 5,157,158 shares of the medical research company’s stock valued at $934,167,000 after acquiring an additional 862,222 shares during the last quarter. 86.20% of the stock is owned by institutional investors and hedge funds.

About IQVIA

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.